Belgian biotechnology company developing in vivo cell and gene therapies for cancer
Belgian biotechnology company developing in vivo cell and gene therapies for cancer. Its ENaBL platform uses targeted lentiviral vectors to deliver genetic instructions to immune cells, enabling CAR-T cells to be generated in vivo through an intravenous injection. The approach aims to make cell therapies more accessible and may also be applied to immune-mediated diseases.